Nanocomposite treatment reduces disease and lethality in a murine model of acute graft-versus-host disease and preserves anti-tumor effects

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Bernardes, Priscila T T ^a   Rezende, Bárbara M ^a   Resende, Carolina B ^a   De Paula, Talles P ^a   Reis, Alesandra C ^a   Gonçalves, William A ^a   Vieira, Elias G ^a   Pinheiro, Maurício V B ^a   Souza, Danielle G ^a   Castor, Marina G M ^a   Teixeira, Mauro M ^a   Pinho, Vanessa ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FULLEROL; GAMMA INTERFERON; LIVER PROTECTIVE AGENT; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; N ACETYL BETA GLUCOSAMINIDASE; RANTES; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FULLERENE DERIVATIVE; NANOCOMPOSITE;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL TRANSLOCATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; INTESTINE INJURY; LIVER INJURY; LIVER LEVEL; LIVER PROTECTION; MORBIDITY; MORTALITY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; SURVIVAL RATE; ADVERSE EFFECTS; ANIMAL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CHEMISTRY; CYTOLOGY; DBA MOUSE; DISEASE MODEL; GRAFT VS HOST DISEASE; INFLAMMATION; LIVER; MACROPHAGE; METABOLISM; NEUTROPHIL; PATHOLOGY; TUMOR CELL LINE;

BACTERIA (MICROORGANISMS); MURINAE; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FULLERENES; GRAFT VS HOST DISEASE; INFLAMMATION; LIVER; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NANOCOMPOSITES; NEUTROPHILS; REACTIVE OXYGEN SPECIES;

EID: 84929483817     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123004     Document Type: Article

References (48)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009; 373 (9674): 1550-61. doi: 10.1016/S0140-6736(09)60237-3 PMID: 19282026
2. Choi SW, Levine JE, Ferrara JL. Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am. 2010; 30 (1): 75-101. doi: 10.1016/j.iac.2009.10.001 PMID: 20113888
3. Castor MGM, Rezende B, Resende CB, Alessandri AL, Fagundes CT, Sousa LP, et al. The CCL3/Macrophage Inflammatory Protein-1a-Binding Protein Evasin-1 Protects from Graft-versus-Host Disease but Does Not Modify Graft-versus-Leukemia in Mice. J Immunol. 2010; 184 (5): 2646-2654. doi: 10.4049/jimmunol.0902614 PMID: 20100934
4. Castor MGM, Rezende BM, Bernardes PTT, Vieira AT, Vieira ELM, Arantes RME, et al. PI3K-controls leukocyte recruitment, tissue injury, and lethality in a model of graft-versus-host disease in mice. Journal of Leukocyte Biology. 2011; 89 (6): 955-964. doi: 10.1189/jlb.0810464 PMID: 21402770
5. Castor MGM, Rezende BM, Resende CB, Bernardes PTT, Cisalpino D, Vieira AT, et al. Platelet-activating factor receptor plays a role in the pathogenesis of graft-versus host disease by regulating leukocyte recruitment, tissue injury, and lethality. Journal of Leukocyte Biology. 2012; 91 (14): 629-639.
6. Penack O, Holler E, Van den Brink MRM. Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood. 2010; 115 (10): 1865-1872. doi: 10.1182/blood-2009-09-242784 PMID: 20042727
7. Schroeder MA, Di Persio JF. Mouse models of graft-versus-host disease: advances and limitations. Disease Models & Mechanisms. 2011; 4 (3): 318-333.
8. Ferrara JL. Novel strategies for the treatment and diagnosis of graft-versus-host disease. Best Practice & Research Clinical Hematology. 2007; 20 (1): 91-97.
9. Choi JH, Yoon H, Min CK, Choi EY. Effects of pre-conditioning dose on the immune kinetics and cytokine production in the leukocytes infiltrating GVHD tissues after MHC-matched transplantation. Immune Network. 2011; 11 (1): 68-78. doi: 10.4110/in.2011.11.1.68 PMID: 21494376
10. Jacobsohn DA, Vogelsang GB. Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr. Pharm. Des. 2004; 10 (11): 1195-1205. PMID: 15078135
11. Kroto AW, Heath JR, O'Brien SC, Smalley RE. C60: Buckminsterfullerene. Nature. 1985; 318 (14): 162-163.
12. Roberts JE, Wielgus AR, Boyes WK, Andley U, Chignell CF. Phototoxicity and Cytotoxicity of Fullerol in Human Lens Epithelial Cells. Toxicol Appl Pharmacol. 2008; 228 (1): 49-58. doi: 10.1016/j.taap.2007.12.010 PMID: 18234258
13. Dugan LL, Lovett KL, Quick J, Lotharius TT, O'Malley KL. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord. 2001; 7 (3): 243-246. PMID: 11331193
14. Injac R, Perse M, Obermaje N, Djordjevic-Millic V, Prijatelj M, Djordjevic A, et al. Potential hepatoprotective effects of fullerenol C60(OH)24 in doxorubicin-induced hepatotoxicity in rats with mammary carcinomas. Biomaterials 2008; 29 (24-25): 3451-3460.
15. Injac R, Perse M, Cerne M, Nejca P, Radic N, Govedarica B, et al. Protective effects of fullerenol C60 (OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials. 2009; 30 (6): 1184-1196. doi: 10.1016/j.biomaterials.2008.10.060 PMID: 19046599
16. Quick KL, Ali SS, Arch R, Xiong C, Wozniak D, Dugan LL. A carboxyfullerene SOD mimetic improves cognition and extends the lifespan of mice. Neurobiol Aging. 2008; 29 (1): 117-128. PMID: 17079053
17. Yudoh k, Karasawa R, Masuko K, Kato T. Water-soluble fullerene (C60) inhibits the development of arthritis in the rat model of arthritis. International Journal of Nanomedicine. 2009; 4: 217-225. PMID: 19918368
18. Dordevich A, Bogdanovich G. Fullerenol-a new nanopharmaceutic? Arch Oncol. 2008; 16 (3-4): 42-45.
19. Alves GC, Ladeira LO, Righi A, Krambrock K, Calado HD, Gil RPF, et al. Synthesis of C60(OH)18-20 in Aqueous Alkaline Solution Under O2-Atmosphere. J. Braz. Chem. Soc. 2006; 17 (6): 1186-1190.
20. Husebo LO, Sitharaman B, Furukawa K, Kato T, Wilson LJ. Fullerenols Revisited as Stable Radical Anion. Journal of the American Chemical Society. 2004; 126 (38): 12055-12064. PMID: 15382940
21. Sardenberg RB, Teixeira CE, Pinheiro M, Figueiredo JMA. Nonlinear Conductivity of Fullerenol Aqueous Solutions. ACS Nano. 2011; 25, 5 (4:): 2681-2686
22. Barcelos LS, Talvani A, Teixeira AS, Cassali GD, Andrade SP, Teixeira MM. Production and in vivo effects of chemokines CXCL1-3/KC and CCL2/JE in a modelo of inflammatory angiogenesis in mice. Inflamm. Res. 2004; 53 (10): 576-584. PMID: 15597153
23. Souza DG, Pinho V, Cassali GD, Poole S, Teixeira MM. Effect of a BLT receptor antagonist in a model of severe ischemia and reperfusion injury in the rat. Eur J Pharmacol. 2002; 440 (1): 61-69. PMID: 11959089
24. Amaral SS, Oliveira AG, Marques PE, Quintão JLD, Pires DA, Resende RR, et al. Altered responsiveness to extracellular ATP enhances acetaminophen hepatotoxicity. Cell Commun Signal. 2013; 11 (1): 2-14. doi: 10.1186/1478-811X-11-2 PMID: 23305203
25. Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW. Infiuence of intestinal bacterial decontamination using metronidazole and ciprofioxacin or ciprofioxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: Final results and long-term follow-up of an open-label prospective randomized trial. Blood. 1999; 93 (10): 3267-3275. PMID: 10233878
26. Irani JL, Cutler CS, Whang EE, Clancy TE, Russel S, Swanson RS, et al. Severe acute gastro-intestinal graft-vs.-host disease: An emerging surgical dilemma in contemporary cancer care. Arch. Surg. 2008; 143 (11): 1041-1045. doi: 10.1001/archsurg.143.11.1041 PMID: 19015460
27. Kim BK, Chung KW, Sun HS, Suh JS, Min WS, Kang CS, et al. Liver disease during the first post-transplant year in bone marrow transplantation recipients: retrospective study. Bone Marrow Transplantation. 2000; 26 (2): 193-197. PMID: 10918430
28. Fuji N, Takenaka K, Shinagawa K, Ikeda K, Maeda T. Hepatic graft-versus-host disease presenting as an acute hepatitis afterallogeneic peripheral blood stem cell transplantation. Bone Marrow Transplantation. 2001; 27 (9): 1007-1010. PMID: 11436113
29. Robb RJ, Hill GR. The interferon-dependent orchestration of innate and adaptive immunity after transplantation. Blood. 2012; 119, 5351-5358. doi: 10.1182/blood-2012-02-368076 PMID: 22517908
30. Tuncer HH, Rana N, Milani C, Darko A, Al-Homsi SA. Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. World J. Gastroenterol. 2012; 18 (16): 1851-1860. doi: 10.3748/wjg.v18.i16.1851 PMID: 22563164
31. Serody JS, Burkett SE, Panoskaltsis-Mortari A, Cashin JNG, McMahon E, Matsushima GK, et al. Tlymphocyte production of macrophage inflammatory protein-1α is critical to recruitment of CD8+ T cells to the liver, lung, and spleen during graft-versus-host disease. Blood. 2000; 96 (9): 2973-2980. PMID: 11049973
32. Bouazzaoui A, Spacenko E, Muller G, Miklos S, Huber E, Holler E, et al. Chemokine and chemokine receptor expression analysis in target organs of acute graft-versus-host disease. Genes Immun. 2009; 10 (8): 687-701. doi: 10.1038/gene.2009.49 PMID: 19571824
33. Wysocki CA, Panoskalsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. Blood. 2005; 105 (11): 4191-4199. PMID: 15701715
34. El-Hayek JM, Rogers TE, Brown GR. The role of TNF in hepatic histopatological manifestations and hepatic CD8+ T cell alloresponses in murine MHC class I disparate GVHD. J Leukocyte Biol. 2005; 78 (4): 1001-1007. PMID: 16081594
35. Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu S, Zakrzewski JL, et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood. 2005; 106 (9): 3322-3330. PMID: 16037386
36. Strasser SI, Shulma HM, Flowers ME, Reddy R, Margolis DA, Prumbaum M, et al. Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis. Hepatology. 2000; 32 (6): 1265-1271:. PMID: 11093733
37. Krusic PJ, Wasserman E, Keizer PN, Morton JR, Preston KF. Radical Reactions of C60. Science. 1991; 254 (22): 1183-1185.
38. Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, Moussa F. [60] fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 2005; 5 (12): 2578-2585. PMID: 16351219
39. Da Rocha AM, Ferreira JR, Barros DM, Pereira TCB, Bogo MR, Oliveira S, et al. Gene expression and biochemical responses in brain of zebrafish Danio rerio exposed to organic nanomaterials: Carbon nanotubes (SWCNT) and fullerenol (C60(OH)18-22(OK4)). Comp Biochem Physiol A Mol Integr Physiol. 2013; 165 (4): 460-467. doi: 10.1016/j.cbpa.2013.03.025 PMID: 23542748
40. Bao S, Carr EDJ, Xu YH, Hunt NH. Gp91phox contributes to the development of experimental inflammatory bowel disease. Immunology and Cell Biology. 2011; 89: 853-860. doi: 10.1038/icb.2011.4 PMID: 21321580
41. Beelen DW, Haralambie E, Brandt H, Linzenmeier G, Muller KD, Quabeck K, et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood. 1992; 80 (10): 2668-2676. PMID: 1421380
42. Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: Final results and long-term follow-up of an open-label prospective randomized trial. Blood. 1999; 93 (10): 3267-3275. PMID: 10233878
43. Irani JL, Cutler CS, Whang EE, Clancy TE, Russell S, Swanson RS, et al. Severe acute gastrointestinal graft-vs-host disease an emerging surgical dilemma in contemporary cancer care. Arch Surg. 2008; 143 (11): 1041-1045. doi: 10.1001/archsurg.143.11.1041 PMID: 19015460
44. Rezende BM, Bernardes PTT, Resende CB, Arantes RME, Souza DG, Braga FC, et al. (2013) Lithothamnion muelleri Controls Inflammatory Responses, Target Organ Injury and Lethality Associated with Graft-versus-Host Disease in Mice. Mar. Drugs. 2013; 11 (7): 2595-2615. doi: 10.3390/md11072595 PMID: 23873335
45. Vago L, Toffalori C, Ciceri F, Fleischhauer K. Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia. Semin Oncol. 2012; 39 (6): 707-715. doi: 10.1053/j.seminoncol.2012.09.009 PMID: 23206847
46. Trpkovic A, Markovic BT, Trajkovic V. Toxicity of pristine versus functionalized fullerenes: mechanisms of cell damage and the role of oxidative stress. Arch Toxicol. 2012; 86 (12): 1809-1827. doi: 10.1007/s00204-012-0859-6 PMID: 22562437
47. Baati T, Bourasset F, Gharbi N, Njim L, Abderrabba M, Kerkeni A, et al. The prolongation of the lifespan of rats by repeated oral administration of [60]fullerene. Biomaterials. 2012; 33 (19): 4936-4946. doi: 10.1016/j.biomaterials.2012.03.036 PMID: 22498298
48. Britto RS, Garcia ML, Rocha MA, Flores JA, Pinheiro BMV, Monserrat JM, et al. Effects of carbon nanomaterials fullerene C60 and fullerol C60(OH)18 22 on gills of fish Cyprinus carpio (Cyprinidae) exposed to ultraviolet radiation. Aquatic Toxicology. 2012; 114-115: 80-87.